2. Department of Cardiology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia, China
3. Norfolk and Norwich University Hospital, Norwich, UK
4. Department of Anesthesiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5. Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore; National Heart Research Institute Singapore, National Heart Centre, Singapore; Yong Loo Lin School of Medicine, National University Singapore, Singapore; The Hatter Cardiovascular Institute, University College London, United Kingdom; Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan; Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please download the PDF. Download full article (PDF)
Methods and results: 24 prospective studies (44972 patients) were included. Patients with an isolated elevation of cardiac biomarkers, had increased risk of all-cause mortality when compared to those with no elevations (cardiac troponin I: odds ratio (OR) 1.42, 95% confidence interval (CI) 1.19-1.69; creatine kinase-MB isoenzyme (CK-MB) OR 1.43, 95% CI 1.19-1.70). For the dose-response analysis, elevations of cardiac troponin I >3x or CK-MB>1x99th percentile upper reference limit (URL) were associated with increased mortality (cardiac troponin I: OR 1.51 95% CI 1.05-2.17; CK-MB: OR 1.25, 95% CI 1.05-1.48). The pooled OR of mortality for each 3xURL increment of cardiac troponin I or CK-MB were 1.33 (95% CI 1.15-1.53) and 1.38 (95% CI 1.30 -1.47).
Conclusions: We found a positive dose-response relationship between isolated cardiac troponin I and CK-MB with all-cause mortality and elevated cardiac troponin I > 3x or CK-MB > 1x the 99th percentile URL was associated with the increased risk of mortality.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com